Open in app
Sign inGet started
GLP-1 agonists like Ozempic look set to transform the world

GLP-1 agonists like Ozempic look set to transform the world

The potential impacts are dramatic, far-reaching, and laced with uncertainty
Go to the profile of Tom Bruss
Tom Bruss
We know ultra-processed foods are bad for us, but we still don’t know why

We know ultra-processed foods are bad for us, but we still don’t know why

Here’s why this uncertainty matters, and what it means for public policy
Go to the profile of Tom Bruss
Tom Bruss
Football: do congested match schedules actually increase injury risk?

Football: do congested match schedules actually increase injury risk?

Here’s what the current research can tell us
Go to the profile of Tom Bruss
Tom Bruss
Knife crime in England and Wales: a summary in numbers

Knife crime in England and Wales: a summary in numbers

A data-driven breakdown, using figures published by the Office for National Statistics
Go to the profile of Tom Bruss
Tom Bruss
About The Economist’s TakeLatest StoriesArchiveAbout MediumTermsPrivacyTeams